Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-24T12:09:04.356Z Has data issue: false hasContentIssue false

A Comparison Between Manic Patients With or Without Antipsychotic Continuation Treatment: Data from a 12-months Follow-up Study at Mood Disorder Unit of San Raffaele–Turro Hospital

Published online by Cambridge University Press:  23 March 2020

S. Brioschi
Affiliation:
IRCCS San Raffaele-Turro, Division of Neuroscience, Milano, Italy
D. Delmonte
Affiliation:
IRCCS San Raffaele-Turro, Division of Neuroscience, Milano, Italy
C. Locatelli
Affiliation:
IRCCS San Raffaele-Turro, Division of Neuroscience, Milano, Italy
L. Franchini
Affiliation:
IRCCS San Raffaele-Turro, Division of Neuroscience, Milano, Italy
B. Barbini
Affiliation:
IRCCS San Raffaele-Turro, Division of Neuroscience, Milano, Italy
C. Colombo
Affiliation:
Vita-Salute University, San Raffaele Hospital, Division of Neuroscience, Milano, Italy

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Several studies suggest that in severe bipolars there is a long-term benefit in continuing antipsychotic therapy plus a mood stabilizer also after remission from a manic episode. Nevertheless, the long-term use of antipsychotics is associated with significant side effects which can interfere with patient global functioning. In this sense, antipsychotics should not be continued unless the benefits outweight the risks.

Objectives

The present study describes the course of illness between bipolar patients remitted from a manic episode, in continuation treatment with or without antipsychotic therapy during a 12-months follow-up period.

Methods

Cinquante-six bipolars (22 male and 44 female) remitted (Young < 12) from a severe manic episode were observed during a 12-months follow-up. According to clinical judge, as continuation treatment, 21/56 (37.5%) took antipsychotic plus mood stabilizer (AP + MS); 35/56 (62.5%) took mood stabilizers monotherapy (MS). During follow-up period YMRS and HAM-D were administered at 6th and 12th month to verify remission.

Results

At the end of follow-up up, 33/56 patients (58.9%) maintained remission, 23/56 (41.1%) relapsed (56.5% depressive, 31.4% manic). The greater number of relapses occurred within 6th month: 16/56 (28.8%). In AP + MS group 12/21 patients relapsed (57.14%); in MS group 11/35 patients relapsed (31.4%). No statistical difference between the two continuation treatment strategies was observed (Chi-square = 3.586; P = 0.06).

Conclusions

Our data confirm the efficacy of mood stabilizers monotherapy in long-term treatment of our severe (psychotic features, revolving-doors) bipolar patients. In fact, once the remission was obtained, the clinical choice of discontinuing antipsychotic therapy did not worsen the course of illness without a higher risk of relapse.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster walk: Anxiety disorders and somatoform disorders
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.